THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY. - THE EFFECTS OF IGF-I IN LIVER CIRRHOSIS.

Foundation for Liver Research0 个研究点开始时间: 2012年4月3日最近更新: 2012年5月29日

适应症

试验速览

暂无简介。

•18-70 year old.
•Confirmed diagnosis of liver cirrhosis by laparoscopy, liver biopsy and/or clinical, biochemical and imaging studies.
•Child-Pugh score 6 or more.
•Plasma IGF-I level below the lower 2.5th percentile and adjusted for age (plasma IGF-I ? -2 SD Z-score).
•Willing and able to give a written informed consent to participate in the study, including all study procedures and follow-up visits.
•Alcohol abstinence for at least 3 months before entering the study.
•Eligible for liver transplantation, and being put on the liver transplant waiting list.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 6
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Tense ascites requiring repeated paracenteses (two or more in the preceding year).
•Severe peripheral edema.
•Hospitalization for gastrointestinal bleeding, spontaneous bacterial peritonitis or other life-threatening complications within 3 months before entering the study.
•Episode of encephalopathy requiring protein restriction, or hepatic encephalopathy that precludes participation.
•Drug abuse.

发起方

Foundation for Liver Research